"The National Cancer Centre Singapore (NCCS) is a leading national and regional tertiary cancer centre with specialists who are experts in treating cancer. NCCS attends to the majority of cancer cases in Singapore’s public healthcare sector. In addition to offering holistic and multidisciplinary oncology care, our clinicians and scientists collaborate with local and international partners to conduct robust, cutting-edge clinical and translational research. To achieve the vision of being a global leading cancer centre, NCCS offers world class care and shares its depth of experience and expertise by training local and overseas medical professionals."

During the past decade, National Cancer Centre Singapore conducted 164 clinical trials. In the 10-year time frame, 164 clinical trials started and 49 clinical trials were completed, i.e. on average, 29.9% percent of trials that started reached the finish line to date. In the past 5 years, 72 clinical trials started and 29 clinical trials were completed. i.e. 40.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Cancer Centre Singapore" #1 sponsor was "National Cancer Centre, Singapore" with 89 trials, followed by "Pfizer" with 12 trials sponsored, "Bayer" with 11 trials sponsored, "Boehringer Ingelheim" with 8 trials sponsored and "Hoffmann-La Roche" with 8 trials sponsored. Other sponsors include 119 different institutions and companies that sponsored additional 72 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Cancer Centre Singapore" #1 collaborator was "National Medical Research Council (NMRC), Singapore" with 12 trials as a collaborator, "National Cancer Centre, Singapore" with 10 trials as a collaborator, "Singapore General Hospital" with 9 trials as a collaborator, "Duke-NUS Graduate Medical School" with 7 trials as a collaborator and "National Cancer Institute (NCI)" with 7 trials as a collaborator. Other collaborators include 159 different institutions and companies that were collaborators in the rest 118 trials.

According to Clinical.Site data, the most researched conditions in "National Cancer Centre Singapore" are "Breast Cancer" (21 trials), "Hepatocellular Carcinoma" (12 trials), "Colorectal Cancer" (9 trials), "Gastric Cancer" (9 trials) and "Non-Small Cell Lung Cancer" (9 trials). Many other conditions were trialed in "National Cancer Centre Singapore" in a lesser frequency.

Most popular intervention types in "National Cancer Centre Singapore" are "Drug" (189 trials), "Other" (27 trials), "Radiation" (18 trials), "Biological" (14 trials) and "Procedure" (12 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (11 trials), "Placebo" (11 trials), "Paclitaxel" (10 trials), "Pembrolizumab" (10 trials) and "Carboplatin" (8 trials). Other intervention names were less common.

The vast majority of trials in "National Cancer Centre Singapore" are 213 trials for "All" genders, 30 trials for "Female" genders and 9 trials for "Male" genders.

Currently, there are NaN active trials in "National Cancer Centre Singapore". 2 are not yet recruiting, 59 are recruiting, 40 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 92 completed trials in National Cancer Centre Singapore, undefined suspended trials, and 25 terminated clinical trials to date.

Out of the total trials that were conducted in National Cancer Centre Singapore, 63 "Phase 1" clinical trials were conducted, 94 "Phase 2" clinical trials and 75 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 22 trials that are defined as “Not Applicable".

National Cancer Centre Singapore has several departments that took part in Clinical trials: "National Cancer Centre; Medical Oncology" - 25 trials